Although evidence suggests that genetic variants in SCN9A are associated with distinct pain perception in oxaliplatin-treated cancer patients, the role of Nav1.7 mediating oxaliplatin-induced pain remains controversial [35,153]. Here, SCN9A is linked to cancer.